Possible suppressive effects of baricitinib on serum IL-22 levels in atopic dermatitis

J Dermatol Sci. 2022 Jun;106(3):189-192. doi: 10.1016/j.jdermsci.2022.04.006. Epub 2022 Apr 14.

Authors

Akihiko Uchiyama¹, Chisako Fujiwara², Yuta Inoue², Mai Ishikawa², Sei-Ichiro Motegi²

Affiliations

¹ Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, Japan. Electronic address: akihiko1016@gunma-u.ac.jp.
² Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, Japan.

PMID: 35459598
DOI: 10.1016/j.jdermsci.2022.04.006

No abstract available

Keywords: Atopic dermatitis; Baricitinib; IL-22.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Azetidines* / pharmacology
Azetidines* / therapeutic use
Dermatitis, Atopic* / drug therapy
Humans
Interleukin-22
Interleukins
Purines
Pyrazoles
Sulfonamides

Substances

Azetidines
Interleukins
Purines
Pyrazoles
Sulfonamides
baricitinib